Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo

Area of Science:

• Biochemistry
• Molecular Biology
• Endocrinology

Background:

• Plasma cell membrane glycoprotein-1 (PC-1/ENPP1) overexpression inhibits insulin signaling.
• Genetic variations and elevated PC-1 levels are linked to type 2 diabetes.
• PC-1 inhibition is a proposed therapeutic strategy for type 2 diabetes, but its efficacy in improving insulin sensitivity requires validation.

Purpose of the Study:

• To investigate whether suppressing PC-1 expression or inhibiting its function improves insulin sensitivity.
• To evaluate the therapeutic potential of PC-1 inhibition for type 2 diabetes.

Main Methods:

• Transient overexpression of PC-1 in HEK293 cells to assess effects on insulin receptor tyrosine phosphorylation.
• PC-1 knockdown using siRNA in HuH7 human hepatoma cells to measure insulin-stimulated Akt phosphorylation.
• Adenoviral delivery of short hairpin RNA (shRNA) targeting mouse PC-1 (PC-1shRNA) in the livers of db/db mice.
• Assessment of hepatic PC-1 mRNA levels, plasma glucose, and oral glucose tolerance in treated db/db mice.

Main Results:

• PC-1 overexpression inhibited insulin-stimulated insulin receptor tyrosine phosphorylation in HEK293 cells.
• PC-1 knockdown significantly increased insulin-stimulated Akt phosphorylation in HuH7 cells.
• Adenoviral PC-1shRNA treatment in db/db mice resulted in ~80% lower hepatic PC-1 mRNA.
• Treated db/db mice exhibited ~30% lower fed plasma glucose, ~25% lower fasting plasma glucose, and significantly improved oral glucose tolerance.

Conclusions:

• Suppression of PC-1 expression enhances insulin sensitivity in vitro.
• PC-1 knockdown in the liver of diabetic mice improves glucose metabolism and insulin sensitivity.
• These findings support PC-1 inhibition as a viable therapeutic strategy for managing type 2 diabetes.